When are hip joint injections considered

Hip joint injections are most often considered when hip pain or stiffness is still limiting day-to-day function despite the usual first steps (for example, hip-focused physiotherapy, activity changes, weight management where relevant, and simple pain medicines), and imaging suggests the hip joint is not yet at an “end-stage” point. In this setting—often early-to-moderate hip osteoarthritis—an ultrasound-guided injection can be used as an outpatient procedure to reduce symptoms for a period of time, rather than as a cure for arthritis.

Another common scenario is diagnostic uncertainty: groin or buttock pain can overlap with referred pain from elsewhere, and a precisely placed local anaesthetic injection into the hip joint is sometimes used to check whether the hip joint is the main pain generator. In a systematic review of patients with co-existent hip and spine osteoarthritis, diagnostic hip injections showed pooled sensitivity of about 0.97 and specificity around 0.9 for predicting pain relief after hip surgery, although the authors noted limitations in the evidence base.

A consultant discussion at Lincolnshire Hip typically frames injection choices around the aim—fast symptom control versus joint-preserving options—along a spectrum:

• Corticosteroid: usually the fastest onset, typically short-term relief over weeks to a few months.
• Hyaluronic acid (viscosupplementation): slower onset and modest benefit in some studies; overall hip evidence is low–moderate quality and mixed.
• PRP (platelet-rich plasma): RCTs in early hip osteoarthritis suggest similar or sometimes longer-lasting symptom improvement compared with HA at 2–6 months, with some follow-up to around 12 months.
• Emerging biologics (mFAT/Lipogems, BMC/BMA): small, mostly uncontrolled hip studies suggest pain and function improvements (often reported at 6–12 months), but certainty remains limited.
• Injectable scaffolds for focal cartilage defects (for example ChondroFiller-style collagen matrices): a niche hip-preservation option for discrete chondral defects, supported mainly by small case series.

Across hip injection studies, results vary widely: one review reported that around 20% of patients get no meaningful relief, and the aim is usually improved pain and function for weeks to months, not a guaranteed avoidance of hip replacement. When a hip replacement is already being planned, observational evidence suggests avoiding corticosteroid injections within 3 months of surgery because infection risk is higher in that window.

To keep the pathway description practical rather than repetitive, service logistics are kept to one note: Lincolnshire Hip offers hip assessment locally in Grantham or Sleaford, and patients can access a consultation without a GP referral.

Why Lincolnshire Hip uses ultrasound guidance

Real-time ultrasound is used at Lincolnshire Hip for hip joint injections because the hip sits deep beneath muscle, and a few millimetres can be the difference between medicine reaching the joint space or ending up in surrounding soft tissue. With ultrasound, the clinician can see the joint line and advance the needle under live imaging, rather than relying on surface “landmarks” alone.

Accuracy: getting the medicine into the hip joint

A systematic review and meta-analysis in the British Journal of Sports Medicine reported near-perfect accuracy for ultrasound-guided hip joint injections (pooled around 98–100%), compared with substantially lower accuracy for landmark-guided techniques (often around the low-70% range). A smaller study that checked placement with contrast imaging found 11 out of 11 ultrasound-guided hip injections were intra-articular, supporting the same point: ultrasound materially reduces the chance of a misplaced injection.

Safety: seeing key structures while guiding the needle

Ultrasound also helps with safety around the front of the hip, where the femoral artery, femoral vein and femoral nerve lie close to the path a needle may take. Technique guidance highlights that visualising these structures and the needle tip in real time supports safer needle positioning, particularly in slimmer patients or those with altered anatomy after prior procedures.

What the ultrasound-guided set-up looks like

In clinic, this is typically done in an outpatient room with an ultrasound machine next to the examination couch. Gel is placed on the skin at the front of the hip and a probe is moved to obtain a clear view of the hip joint; a fine needle is then guided towards the joint under continuous imaging before the chosen injectate is delivered.

Diagnostic injections: confirming the hip joint as the pain source

The same accuracy is valuable for diagnostic hip joint injections, where a small volume of local anaesthetic is placed inside the joint to see whether pain settles clearly for a short period. Systematic review evidence and a prospective study in patients with atypical hip pain suggest that a strong temporary response can support the hip joint as the main pain generator, while a poor response makes alternative or additional sources more likely (for example, referred pain).

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Hyaluronic acid and steroid injections what to expect

Most decisions between corticosteroid (cortisone) and hyaluronic acid (HA) hip joint injections come down to the trade-off between speed and staying power. In hip osteoarthritis trials (for example the 2006 Qvistgaard study comparing HA, steroid and saline), steroid tends to act sooner, while HA (viscosupplementation) is usually discussed as a joint-“lubricating” option with a slower build-up of effect, and neither is presented as a cartilage-rebuilding treatment.

Steroid injections into the hip joint are generally used for short-term pain control—often during a flare of osteoarthritis symptoms—because relief may begin within days, may peak over the next few weeks, and often fades over weeks to a few months. Patient information leaflets also stress that improvement is not always immediate and can take days or weeks, and that a brief increase in pain (a “flare”) can happen before things settle.

HA injections for the hip joint commonly have a slower onset. Patient-facing guidance describes it as potentially taking several weeks before any benefit is noticed, and—when it works—relief may last many months in some people, with wide variation between individuals. A 2024 Canadian evidence review concluded that the hip OA evidence base for HA is still low–moderate quality, with small heterogeneous studies, and there is not firm proof that HA reliably delays hip replacement; that uncertainty is part of why clinicians do not frame it as a guaranteed “surgery-delaying” treatment.

Across hip injection studies more broadly (including steroid and HA), response is uneven. One review reported that around 20% of patients do not get meaningful relief at all, some people feel only very short-lived benefit (≤2 weeks), and others get relief lasting beyond 2 weeks. This range is useful when deciding whether a first injection is worth trying, and whether repeating an injection is likely to be worthwhile.

On the day, a typical ultrasound-guided hip joint injection pathway at Lincolnshire Hip mirrors NHS-style “day case” descriptions: the skin at the front of the hip is cleaned, local anaesthetic is used to numb the area, and a needle is guided into the hip joint under imaging before the medication is injected. Many services use a mixture of steroid plus local anaesthetic for cortisone injections; the anaesthetic can cause temporary numbness or a short-lived “good patch”, while the steroid effect (if it occurs) often takes longer. After observation, patients usually go home the same day, and are commonly advised to avoid heavy activity for 24–48 hours.

• Timeline to notice change: steroid may help in days (sometimes longer); HA often takes weeks.
• How long it may last: steroid often weeks to a few months; HA can be months in some responders.
• Normal early sensations: temporary numbness from local anaesthetic; a brief pain flare can occur.
• Aftercare anchor: light activity is usually fine, but heavy loading is typically avoided for 24–48 hours.
• When to seek urgent advice: escalating pain with systemic illness (for example fever), spreading redness, or new severe symptoms after an injection warrants prompt medical assessment.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment in Grantham or Sleaford.

Where PRP fits compared with cortisone

A clear way to frame the choice is this: cortisone is mainly about fast, short-term anti-inflammatory pain relief, while PRP is a blood-derived “biologic” option aimed at longer-horizon symptom improvement in earlier-stage hip osteoarthritis—but the best comparative evidence in the hip is PRP versus hyaluronic acid, not PRP versus steroid.

PRP (platelet-rich plasma) is prepared from a patient’s own blood and then injected into the hip joint under imaging. Rather than acting as a simple anti-inflammatory, PRP is generally discussed as supporting the body’s own repair processes within the joint environment. In hip-specific randomised trials, ultrasound-guided PRP has repeatedly shown improvements in pain and function that are at least similar to hyaluronic acid at follow-up points such as 2–6 months, with some studies reporting benefits extending towards ~12 months in parts of the treated group, without consistent proof that PRP is clearly superior to HA in every study.

Directly comparing PRP with cortisone in the hip is harder because robust head-to-head hip RCTs are not established in the same way as PRP-versus-HA trials. Reviews discussing hip injection evidence therefore tend to place PRP and steroid on different “jobs”: steroid as a short-term option, PRP as a hip-preservation-leaning option, with comparisons relying on indirect evidence and clinical reasoning rather than definitive hip trial data.

Practical trade-offs that often shape decisions in clinic include:

• Speed: steroid is typically chosen when rapid symptom settling is the priority (often noticed over days to the first few weeks), whereas PRP is usually framed as slower to declare its benefit.
• How long relief may last: steroid benefit often tails off over weeks to a few months; PRP is discussed as having a chance of more sustained improvement in some people (commonly assessed at 6–12 months in published hip studies).
• Cost and funding: steroid is generally lower-cost; PRP is commonly self-funded and priced accordingly.
• Treatment intent: steroid focuses on reducing inflammation and pain; PRP is positioned as a biologic, hip-joint–preserving approach rather than a “quick fix”.

One reason PRP outcomes can be difficult to predict is that protocols vary across hip studies—single versus multiple injections, and differences in PRP preparation (for example, leukocyte-poor versus leukocyte-rich products). That variability is part of why a Lincolnshire Hip plan typically needs to specify the intended protocol and the realistic outcome window (for example, reviewing response at 2–6 months rather than judging it in the first few days).

Biologic and scaffold options for early hip arthritis

These options sit at the “hip preservation” end of the Lincolnshire Hip injection pathway: they are usually discussed when symptoms and scans suggest early-to-moderate hip osteoarthritis or a localised cartilage problem, and when the aim is to support the hip joint’s own biology rather than simply settling a short-term flare.

Autologous biologics (using the patient’s own tissue)

Two commonly discussed categories are micro-fragmented adipose tissue (mFAT; often referred to by systems such as Lipogems) and bone-marrow–derived injections (described in studies as bone marrow concentrate (BMC) or bone marrow aspirate (BMA)). In broad terms, both start with harvesting a small amount of the patient’s own tissue (fat for mFAT, bone marrow for BMC/BMA), processing it to concentrate potentially helpful cellular and signalling components, and then delivering the prepared product into the hip joint under imaging in an outpatient-style pathway. Published hip outcomes focus on changes in pain and function scores, not proven cartilage “regrowth”.

The most useful “who is this for?” dividing line is often the problem being treated rather than the brand name:

• mFAT (Lipogems-style) for early arthritis symptoms: in a prospective, non-randomised osteoarthritis study (multiple joints including the hip), clinically relevant improvements were reported and were often maintained at 12–24 months; however, joint-mixed cohorts and the lack of a control group limit how confidently this can be translated to hip-only care.
• BMC/BMA for symptomatic hip osteoarthritis: a pilot hip osteoarthritis study reported that a single BMC injection improved patient-reported pain and function for up to 6 months. A separate hip series using BMA reported improvements that, in that cohort, could last as long as 12 months across mild, moderate, and severe radiographic stages—again without a control group.

Taken together, the hip evidence for mFAT and BMC/BMA is best read as “promising but early”: studies suggest some patients may gain months to 1–2 years of symptom improvement, but there are not yet strong, hip-specific comparative trials showing clear advantage over simpler options or defining who reliably responds.

Injectable scaffold options for focal hip cartilage defects (ChondroFiller-style)

A different “candidate profile” is the patient with a contained focal chondral defect in the hip (for example, an acetabular or femoral head cartilage lesion) rather than diffuse, end-stage arthritis. ChondroFiller is described as a cell-free collagen type I matrix; the intended mechanism is an acellular scaffold that supports matrix-induced chondrogenesis by helping recruit the patient’s own cells into the defect environment.

In a hip case series using a thrombin–collagen ChondroFiller matrix, patients showed improvements in hip pain and function scores at follow-up, and MRI often demonstrated partial defect filling—but the evidence remains limited to small, uncontrolled cohorts and mid-term follow-up. That places scaffold injections firmly in the “specialist, carefully selected” category: the intended measure of success is typically better pain and day-to-day function, not guaranteed structural restoration.

Planning hip injections around possible hip replacement

For some people, a hip joint injection is a way to stay active while deciding whether symptoms can be managed without surgery; for others, it is a “bridge” while planning a total hip replacement (total hip arthroplasty). Lincolnshire Hip generally treats injections and hip replacement as parts of the same hip-care pathway, with the sequencing driven by how persistent the pain and stiffness are over time (often measured in months rather than days), and how well the hip responds to earlier non-surgical steps.

When symptoms could plausibly be coming from more than one place—classically the hip joint versus the lumbar spine or sacroiliac region—an image-guided diagnostic injection of local anaesthetic into the hip joint can be useful. A systematic review in patients with coexistent hip and spine osteoarthritis reported pooled sensitivity of about 0.97 and specificity around 0.9 for predicting pain relief after hip surgery, meaning a marked temporary reduction in pain after an accurately placed injection tends to point towards the hip joint as a major pain generator (while still not being a standalone “perfect test”). A prospective study (published on PubMed) similarly described ultrasound-guided diagnostic hip injection as useful in confirming hip pathology when the presentation is atypical.

The main timing “red flag” before hip replacement is corticosteroid (cortisone). A large meta-analysis (over 300,000 patients) and later systematic reviews have found that a corticosteroid hip joint injection within 3 months before total hip arthroplasty is associated with a higher risk of periprosthetic joint infection (PJI). A 2024 arthroplasty study reported a hazard ratio of about 2.63 for injections given up to 3 months pre-operatively, whereas injections given beyond that window did not show the same level of risk. In practical terms, where hip replacement is likely in the near term, Lincolnshire Hip would typically avoid steroid hip joint injections inside a 3‑month window and make the timing trade-off explicit.

Non-steroid options (such as PRP, hyaluronic acid, or other biologics) may have different risk profiles, but robust hip-specific infection-risk data before hip replacement are limited. For that reason, decisions are usually individualised, and a clear “run-in” period before surgery may still be preferred even when the last injection was not steroid.

A practical takeaway is a simple sequencing framework:

• If the pain source is unclear (hip vs spine/sacroiliac): consider a diagnostic local anaesthetic hip injection to guide whether hip-preserving injections or hip replacement is more likely to help.
• If hip replacement is being planned: avoid corticosteroid injection within 3 months of surgery because of the PJI signal (including HR ~2.6 in 2024 data).
• If surgery is not imminent: hip-preserving injections can be tried with a defined review point (commonly 2–6 months for PRP outcomes in published hip studies).
• If injections repeatedly give little or short-lived benefit: the balance often shifts towards discussing hip replacement rather than cycling further injections.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment in Grantham or Sleaford, including advice on injection timing if hip replacement may be needed later.